Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 5/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799236 | 0.87 | CDK1 (0.36) | CDK1CCNB1GSK3BCCNB2CCNB3 | |
| SCHEMBL1799952 | 0.79 | SLC2A1 (0.33) | CDK1CCNB1GSK3BCCNB2CCNB3 | |
| SCHEMBL1801781 | 0.69 | PTGDR2 (0.39) | PDE4ARAB9A | |
| SCHEMBL1796421 | 0.69 | SLC2A1 (0.43) | SLC2A1 | |
| SCHEMBL1801778 | 0.66 | BRD4 (0.44) | CDK1CCNB1CCNB2CCNB3RAB9A | |
| SCHEMBL1802877 | 0.63 | ROCK1 (0.46) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1723806 | 0.61 | PARP1 (0.40) | SLC2A1 | |
| SCHEMBL2752494 | 0.60 | BRD4 (0.42) | TYK2 | |
| SCHEMBL1150164 | 0.60 | SLC2A1 (0.47) | SLC2A1 | |
| SCHEMBL19626505 | 0.60 | GRM5 (0.52) | ADRA1AADRA1BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2125801-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | CDK1 674/4885CCNB1 2283/4885GSK3B 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.